Inactive Instrument

IntelliPharmaCeutics International Inc. Share Price OTC Bulletin Board

Equities

CA4581733090

Pharmaceuticals

Sales 2021 - Sales 2022 65.73T 54.9L Capitalization 24.67L 21Cr
Net income 2021 -50L -42Cr Net income 2022 -20L -17Cr EV / Sales 2021 -
Net Debt 2021 11.45L 9.57Cr Net Debt 2022 22.42L 19Cr EV / Sales 2022 71.6 x
P/E ratio 2021
-0.65 x
P/E ratio 2022
-0.85 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 98.24%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder - 01/98/01
Chief Executive Officer - 01/98/01
Comptroller/Controller/Auditor - 01/07/01
Members of the board TitleAgeSince
Director/Board Member 69 22/19/22
Chief Executive Officer - 01/98/01
Founder - 01/98/01
More insiders
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.
More about the company